Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
Albuminuria
Cardiovascular risk
Serum uric acid
eGFR
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
06
11
2020
accepted:
30
01
2021
pubmed:
24
3
2021
medline:
24
3
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
Hyperuricemia is commonly observed in patients with chronic kidney disease (CKD). However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification. Our main goal was to study the relationships between serum uric acid and kidney disease measures (namely estimated GFR [eGFR] and albuminuria) in a large cohort of individuals at cardiovascular risk from the URic acid Right for heArt Health (URRAH) Project database. Clinical data of 26,971 individuals were analyzed. Factors associated with the presence of hyperuricemia defined on the basis of previously determined URRAH cutoffs for cardiovascular and all-cause mortality were evaluated through multivariate analysis. Chronic kidney disease was defined as eGFR < 60 ml/min per 1.73 m Mean age was 58 ± 15 years (51% males, 62% with hypertension and 12% with diabetes), mean eGFR was 81 ml/min per 1.73m2 The lower the eGFR the higher the prevalence of hyperuricemia and gout. In subjects with eGFR < 60 ml/min the occurrence of hyperuricemia is about 10 times higher than in those with eGFR > 90 ml/min. The percentage of individuals treated with allopurinol was below 2% when GFR was above 60 ml/min, it increased to 20% in the presence of CKD 3b and rose further to 35% in individuals with macroalbuminuria.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperuricemia is commonly observed in patients with chronic kidney disease (CKD). However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification. Our main goal was to study the relationships between serum uric acid and kidney disease measures (namely estimated GFR [eGFR] and albuminuria) in a large cohort of individuals at cardiovascular risk from the URic acid Right for heArt Health (URRAH) Project database.
METHODS
METHODS
Clinical data of 26,971 individuals were analyzed. Factors associated with the presence of hyperuricemia defined on the basis of previously determined URRAH cutoffs for cardiovascular and all-cause mortality were evaluated through multivariate analysis. Chronic kidney disease was defined as eGFR < 60 ml/min per 1.73 m
RESULTS
RESULTS
Mean age was 58 ± 15 years (51% males, 62% with hypertension and 12% with diabetes), mean eGFR was 81 ml/min per 1.73m2
CONCLUSIONS
CONCLUSIONS
The lower the eGFR the higher the prevalence of hyperuricemia and gout. In subjects with eGFR < 60 ml/min the occurrence of hyperuricemia is about 10 times higher than in those with eGFR > 90 ml/min. The percentage of individuals treated with allopurinol was below 2% when GFR was above 60 ml/min, it increased to 20% in the presence of CKD 3b and rose further to 35% in individuals with macroalbuminuria.
Identifiants
pubmed: 33755930
doi: 10.1007/s40620-021-00985-4
pii: 10.1007/s40620-021-00985-4
pmc: PMC8803667
doi:
Substances chimiques
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-221Subventions
Organisme : Fondazione of the Italian Society of Hypertension
ID : MIOL
Informations de copyright
© 2021. The Author(s).
Références
Kidney Int. 2006 Aug;70(4):800-6
pubmed: 16820784
PLoS One. 2012;7(11):e50046
pubmed: 23209642
Am J Kidney Dis. 2006 Jan;47(1):51-9
pubmed: 16377385
BMC Nephrol. 2018 Apr 24;19(1):95
pubmed: 29699501
Lancet Diabetes Endocrinol. 2015 Jul;3(7):514-25
pubmed: 26028594
Am J Kidney Dis. 2007 Aug;50(2):239-47
pubmed: 17660025
Curr Rheumatol Rep. 2012 Apr;14(2):179-88
pubmed: 22359229
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1921-9
pubmed: 26342044
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Am J Kidney Dis. 2009 May;53(5):796-803
pubmed: 19303683
PLoS One. 2017 Jan 20;12(1):e0170393
pubmed: 28107415
N Engl J Med. 2020 Jun 25;382(26):2493-2503
pubmed: 32579810
High Blood Press Cardiovasc Prev. 2018 Jun;25(2):197-202
pubmed: 29427170
Hypertension. 2020 Feb;75(2):302-308
pubmed: 31813345
Am J Kidney Dis. 2018 Dec;72(6):798-810
pubmed: 30177485
PLoS One. 2015 Jun 01;10(6):e0129797
pubmed: 26029914
N Engl J Med. 2008 Oct 23;359(17):1811-21
pubmed: 18946066
Am J Kidney Dis. 2015 Apr;65(4):543-9
pubmed: 25595565
Arthritis Res Ther. 2012 Aug 17;14(4):R189
pubmed: 22901830
Am J Physiol Renal Physiol. 2019 Jan 1;316(1):F173-F185
pubmed: 30427222
Diabetologia. 2015 Sep;58(9):1993-2002
pubmed: 26049401
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):577-584
pubmed: 28153936
Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93
pubmed: 20538833
J Nephrol. 2020 Aug;33(4):715-724
pubmed: 31933161
Nutr Metab Cardiovasc Dis. 2014 Aug;24(8):921-7
pubmed: 24675005
PLoS One. 2015 Feb 06;10(2):e0118031
pubmed: 25658588
Nephrol Dial Transplant. 2015 Apr;30(4):613-21
pubmed: 25395390
Eur Heart J. 2019 Jun 7;40(22):1778-1786
pubmed: 30844048
Contrib Nephrol. 2018;192:103-109
pubmed: 29393137
PLoS One. 2014 Jun 24;9(6):e100801
pubmed: 24959886
N Engl J Med. 2020 Jun 25;382(26):2504-2513
pubmed: 32579811
Metab Syndr Relat Disord. 2017 Dec;15(10):500-506
pubmed: 29154722
Arthritis Rheum. 2002 Dec 15;47(6):610-3
pubmed: 12522834